In 2009, Fong and colleagues [163] published their results from a phase I trial with the PARP inhibitor olaparib involving 60 tumor patients enriched in BRCA mutation carriers, including 16 hereditary ovarian carcinoma patients. This evidence concerns the gene PARP1 and familial ovarian carcinoma.